Chicago, Il. January 8, 2020: Content Carnivores, LLC, a creative marketing firm deploying proprietary technology, category and creative expertise in regulated industries is supporting 10 clients who are participating at the Biotech Showcase™ 2020, investor conference and/or other events in San Francisco being held simultaneously as the JP Morgan Healthcare Conference, January 12 -16, 2020.
Content Carnivores is honored to be a Silver Sponsor at the Biotech Showcase™ and is pleased to bring its expertise and guidance to outstanding companies who recognize the need to effectively communicate to their audiences.
Content Carnivores works with biotech and medtech (as well as others) companies who are solving some of the toughest problems in healthcare.
This year 10 of our clients will be presenting and/or meeting investors during the JP Morgan Healthcare Conference Week. We are pleased that each company is filling their meeting schedules and brushing up their presentation decks.
We hope you will consider attending a presentation, schedule a meeting, or request their pitch deck to learn more.
Outstanding Companies Worth a Look
Salarius and Nanovalent
Most people have never considered that cancer treatments are developed for adults. But how can that work for non-adults, ie, childhood cancer? Two of our clients are working on Ewing sarcoma (as well as solid tumors, leukemia, etc.) as the start of ambitious pipelines. Interestingly, their approach is unique from the other.
Salarius is potentially creating an epigenetics light switch which can turn on and off cancer cells. They have so far shown terrific success where others, even Celgene, have not. We have more science detail in this white paper.
Nanovalent is a Targeted NanoSphere - based product incorporating Hybrid Polymerized Liposomal Nanoparticle technology. Advantages (beyond the Star Trek implications) are vast improvements in flexibility and cell targeting. For more details on their novel science, check out this site.
Both company’s entry-focus is on refectory pediatric patients who are in dire need and who have not responded to traditional treatment.
We all know people who have been affected by Alzheimer’s. A breakthrough is now ready. We need human trials in the reformulation of a clinically proven compound that eliminates previously limiting side effects.
Aqualung, "ALT", will present new DATA on eNamptor™, a humanized monoclonal antibody (mAb) designed to tackle and limit inflammation ultimately reducing mortality from serious inflammatory disorders...found in our ICU’s! Including ARDS.
Pacylex - leukemia/AML - Oncology
Pacylex may be developing a gem. PCLX-001 is a first-in-kind, small molecule with a novel mechanism of action believed to play a significant role in the development of certain types of blood cancers and solid tumors. They are on path to file an IND within 6-9 months.
PhagoMed, Geovax and Quara.
For generations, antibiotics and vaccines were the answer to bacterial infections, infectious diseases and other life-threatening diseases. Now, new platforms generate amazing ways to fight.
PhagoMed is an Austrian-based biopharma company developing a pipeline of phage or bacterio-phage based candidates. They are developing synthetic bacteria that eat the bad, live bacteria! This also makes drug handling safer and less expensive.
This brings me to GeoVax.
GeoVax's vaccine platform has proven preclinical efficacy in five infectious diseases (Lassa, Ebola, Marburg, Zika, and HIV) and has shown an excellent safety profile in their HIV human clinical trials to date. This builds an excellent scientific foundation on which they are using the MVA platform to build an immuno-oncology program. Like PhagoMed, GeoVax does not deal with live viruses. Instead, they utilize a VLP (virus like particle) tech with so much upside - I could write a book on this company! Here’s a little deeper into their science. Their IO spin is ready for gro2020.
Quara is a handheld bacterial infection/presence diagnostics sensor with applicability well beyond healthcare. Marine life, animal health, food processing, agriculture, etc...anywhere it’s a bad thing to have a bacterial infection. QuaraSense™ will help us utilize the right antibiotics early enough and even provide feedback on insights on drug effectiveness. Multiple perspectives on savings!
They are currently raising money through a Reg D offering and plan to do a Reg A+ later this year.
We’re lucky to work with such great companies - awesome science and the companies themselves, wonderful to work with!
It’s a busy, noisy, exhausting time next week but I have to admit, I just love it! We’re sponsors at the Biotech Showcase so much of our time is there. Please message me or Jeff if you’d like to learn more or meet one of our companies!
Disclaimer: Please note that all of the above companies are clients of our marketing services. We are not broker/dealers and do not make any investment recommendations.
Here's our full disclaimer.
